Significant increase in bio-availability through LBL technology

Capsulution is testing an innovative formulation of active ingredients on animals

Berlin, (PresseBox) - The Berlin-based nanotechnology company Capsulution NanoScience AG has successfully completed a preclinical, in-vivo study on increasing the bio-availability of poorly water-soluble active ingredients. In comparison to the non-formulated substance, a tripling of the bio-availability could be proved certain. With this the Capsulution AG has managed to prove the impressive strength of their patent-protected technology in pharmaceutical developments.

Many active ingredients pose a serious problem for pharmaceutical researchers. They are poorly water-soluble and therefore dissolve very inadequately or only very slowly in bodily fluids, for instance gastric juices. As a result, only a small proportion is dissolved and absorbed via the stomach wall or intestinal mucous membrane into the blood circulation whereas a much larger proportion of the active ingredient is simply excreted. Even among those active ingredient molecules reaching the blood circulation, however, only a small proportion of those reach the organ targeted for treatment. A much larger proportion is passed out with the urine. In this context, developers talk about “poor bio-availability”.

In order to improve bio-availability, pharmaceutical formulators are trying to increase the dissolvability of pharmaceutical substances with poorly water-soluble active ingredients. “We are combining micronising technologies with our LBL-Technology,” explains Christoph Dunmann, Project Director at Capsulution. Thanks to the enlarged surfaces, the stabilizing particles interact more easily with and dissolve more rapidly in the watery bodily fluids. The tenside-free formulations are extremely palatable. By decreasing the therapeutic dose, the danger of side-effects is further reduced.

“In the current study, we investigated the pharmaceutical kinetics of an extremely poor water-soluble model substance with a solubility of less than 40 mg per litre with oral administration in rats,” continued Dunmann. Various nano-particle-based LBL formulations were tested, in which the poly-electrolytes applied as well as the number of layers varied. In comparison to the unformulated active ingredient, the bio-availability in all the LBL formulations was significantly increased.

Following the successful study on animals, Capsulution is setting course for rapid development. A second animal study on the oral bio-availability is already on the programme for the first half of this year. Also planned are the improvement in the formulation of nano-suspensions for intravenous administration and formulations for subcutaneous and intra muscular dosage with an additional depot effect. There is also work on a non-invasive method of bringing active ingredients into the eye.

Capsulution Pharma AG

Capsulution NanoScience AG is a leading company in the field of tailor-made drug-delivery systems and other innovative life science products on the basis of so-called nanocapsules. These nanocapsules are manufactured on the basis of the worldwide patent protected LBL Technology®. Due to their minute size and high level of functionability as well as their extremely reproducible manufacture, the capsules can be used in a diverse number of applications. The nano and micro capsules can be manufactured in any desired size, according to application and endowed with practically any biochemical, electric, optical and magnetic properties.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

„AppliedAI“-Initiative will KI in Deutschland voranbringen

Je­des Jahr ein deut­sches Start-up aus dem Um­feld der Künst­li­chen In­tel­li­genz (KI) in die in­ter­na­tio­na­len Top-100-Lis­ten brin­gen – so lau­tet ei­nes der Zie­le, das sich die In­i­tia­ti­ve „Ap­p­lie­dAI“ auf die Fah­ne ge­schrie­ben hat. Un­ter der Äg­i­de der Baye­ri­schen Staats­re­gie­rung und mit Un­ter­stüt­zung der Tech­ni­schen Uni­ver­si­tät Mün­chen ko­ope­rie­ren 26 For­schung­s­ein­rich­tun­gen und Kon­zer­ne.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.